Health ❯ Medical Research ❯ Clinical Trials

Drug Development

Monoclonal Antibodies Gene-Editing Treatments Therapeutic Targets Neurosurgery JAK2 Inhibitors Regenerative Medicine Innovative Treatments Therapeutic Approaches Targeted Therapies Parkinson's Disease Polilaminina Alopecia Areata Microbiome Science Immunology FDA-Approved Treatments Biosimilars Cancer Treatments PAR1 Targeting Oncology Teclistamab MDM2 Inhibitors

Lilly to Acquire Ajax Therapeutics in Up to $2.3 Billion Blood Cancer Deal

The deal gives Lilly a Type II JAK2 drug that aims to help patients who stop responding to today’s JAK2 therapies.

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

BMS, BioNTech Small-Cell Lung Cancer Drug Posts 76% Tumor Reduction, Advances to Phase III

PAR1 Receptor Drives Lung Lymphatic Remodeling to Accelerate Fluid Clearance